DMPK studies, often referred to as ADMET studies are critical in the drug discovery and development process as they help in determining the viability of a drug candidate. The selection of drug candidates with best ADMET properties enhances the probability of clinical success by helping the drug developers understand the safety and efficacy of the drug. Our objective is to design the studies that are necessary for your molecule in the most efficient and cost effective way.

VIMTA offers the complete range of ADMET studies which are critical for ensuring clinical success. We use in vitro human-based experimental system in combination with in vivo animal systems by using animal species relevant to humans, thus representing the best approach to assess these important drug-like properties before clinical trials. All in vitro and in vivo studies are performed under strict quality control, and we have experience of different administration routes in single or multiple dosing. Our in vitro ADME studies include

Absorption studies
• Parallel Artificial Membrane Permeability Assay (PAMPA)
• Cell permeability assays (CaCO2 and MDCK cells)
• P-gp substrate identification studies using MDR1-MDCK cells
• Everted Gut Sac Permeability Assay

Distribution
• Plasma Protein Binding – mouse, rat, rabbit, dog and human using equilibrium dialysis method
• Plasma / Whole blood stability – mouse, rat, rabbit, dog and human
• Microsomal binding studies
• Blood to plasma ratio

Metabolism
Drug – Drug Interaction studies
• Cytochrome P450 Inhibition (Probe Based)
• Cytochrome P450 Induction in human and animal species

Metabolite Profiling Studies
• Metabolite Identification
• Reaction Phenotyping

Stability Studies
• Microsomal Stability studies (Different Species)
• Hepatocytes Stability studies (Different Species)
• S9 fraction Stability
• Plasma Stability